# STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

> **NCT03548935** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1961 (actual)

## Conditions studied

- Metabolism and Nutrition Disorder
- Overweight or Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT03548935
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-04
- **Primary completion:** 2020-03-30
- **Final completion:** 2021-03-05
- **Target enrollment:** 1961 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03548935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03548935, "STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03548935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*